Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 September 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

From a 52-week low of Rs 95 to a fresh peak of Rs 318, Bafna Pharmaceuticals Ltd has surged over 200% in the past year, defying the broader market’s subdued performance. This remarkable rally culminated in the stock hitting a new 52-week high on 1 Sep 2026, fuelled by a confluence of strong technical signals and sustained price momentum.

At Rs 304.5, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Bafna Pharmaceuticals Ltd locked at its upper circuit of 4.6% on 31 Aug 2026, with buyers queuing and no sellers willing to part with shares.

From a 52-week low of Rs 95 to a fresh peak of Rs 303.85 on 31 Aug 2026, Bafna Pharmaceuticals Ltd has delivered an extraordinary 198.04% return over the past year, significantly outpacing the Sensex’s decline of 3.63%. This remarkable rally is underpinned by a broad alignment of technical indicators signalling sustained momentum.

Surging nearly 193% over the past year, Bafna Pharmaceuticals Ltd has now touched an intraday high of Rs 290.4, closing just 1.93% shy of its 52-week peak. This remarkable price momentum unfolds amid a backdrop of strong technical signals and a market environment where the broader Sensex trades cautiously below key moving averages.

At Rs 291.35, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Bafna Pharmaceuticals Ltd locked at its upper circuit of 4.99% on 28 Aug 2026, with buyers queuing and no sellers willing to part with shares.

At Rs 271.5, sellers were still queuing — but there were no buyers willing to take the other side. Bafna Pharmaceuticals Ltd locked at its lower circuit of 3.24% on 27 Aug 2026, with unfilled sell orders and a frozen price.

Bafna Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 August 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

At Rs 280.6, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Bafna Pharmaceuticals Ltd locked at its upper circuit of 5.0% on 26 Aug 2026, with buyers queuing and no sellers willing to part with shares.

At Rs 267.25, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Bafna Pharmaceuticals Ltd locked at its upper circuit of 4.99% on 25 Aug 2026, with buyers queuing and no sellers willing to part with shares.

At Rs 254.55, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Bafna Pharmaceuticals Ltd locked at its upper circuit of 5% on 24 Aug 2026, with buyers queuing and no sellers willing to part with shares.

Bafna Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 May 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 15 August 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

From a 52-week low of Rs 85.24 to a fresh peak of Rs 296, Bafna Pharmaceuticals Ltd has surged an impressive 253.14% over the past year, outpacing the Sensex which declined by 1.60% in the same period. This remarkable rally culminated in the stock hitting a new all-time high today, buoyed by a confluence of bullish technical indicators and sustained price momentum.

From a 52-week low of Rs 77.01 to a fresh peak of Rs 289, Bafna Pharmaceuticals Ltd has surged over 257% in the past year, significantly outpacing the Sensex's decline of 2.54%. This remarkable rally culminated in a new 52-week high on 7 Aug 2026, fuelled by a confluence of bullish technical indicators and sustained price momentum.

From a 52-week low of Rs 77.01 to a fresh peak of Rs 285, Bafna Pharmaceuticals Ltd has surged an impressive 233.61% over the past year, significantly outpacing the Sensex’s decline of 2.12%. This remarkable rally culminated in a new 52-week high on 6 Aug 2026, fuelled by a confluence of bullish technical indicators and sustained price momentum.

Surging to a new 52-week high of Rs 284.15 on 5 Aug 2026, Bafna Pharmaceuticals Ltd has demonstrated remarkable price momentum, outperforming its sector and the broader market with a 235.91% gain over the past year against the Sensex's decline of 2.57%.